08 September 2010
GENERICS, the bane of the research-based pharmaceutical industry, are a very important aspect of the health care industry to monitor, as more and more governments around the world are pushing for their greater use in order to contain health care budgets, while the launch of copy products on patent expiry - and often even before this actually occurs - can wipe billions of dollars off drugmakers’ revenues.6 September 2010
The government in Greece last week released a new official list of drugs including more than

6 September 2010
In another move by a pharmaceutical major to prop up falling revenues from original drugs in
6 September 2010
US biotechnology firm Celgene Corporation (Nasdaq: CELG) said on Friday it has received a Paragraph
3 September 2010
The value of Argentina's pharmaceutical market is calculated to have reached 12.64 billion
2 September 2010
India’s largest drugmaker, Ranbaxy Laboratories (which is 64% owned by Japanese drug major
1 September 2010
On August 27, 2010 the Brazilian Patent and Trademark Office (INPI) made public on its web
27 August 2010
Fast-growing Jordan-headquartered Hikma Pharmaceuticals (LSE: HIK; Nasdaq Dubai: HIK) has
7 September 2010 | North Africa Journal
6 September 2010 | Gulf Times
6 September 2010 | Alibaba News Channel
6 September 2010 | Richmond Times Dispatch
5 September 2010 | Business Standard
3 September 2010 | Toronto Star
2 September 2010 | healthzone.ca
2 September 2010 | Chicago Tribune
2 September 2010 | FiercePharma
2 September 2010 | Trading Markets (press release)
1 September 2010 | Proactive Investors USA & Canada